Virtus LifeSci Biotech Clinical Trials ETF
18 hedge funds and large institutions have $8.24M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
2.01% less ownership
Funds ownership: 36.3% → 34.29% (-2%)
Holders
18
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$475K | |
| 2 | +$224K | |
| 3 | +$158K | |
| 4 |
SG Americas Securities
New York
|
+$101K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$95.3K |
Top Sellers
| 1 | -$747K | |
| 2 | -$352K | |
| 3 | -$55.3K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$24.8K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$5K |